Schiffer Eric
Mosaiques Diagnostics and Therapeutics AG, Mellendorfer Str. 7-9, 30625 Hannover, Germany.
World J Urol. 2007 Dec;25(6):557-62. doi: 10.1007/s00345-007-0203-6. Epub 2007 Aug 10.
Novel biomarkers for prostate cancer (PCa) are currently being assessed for utility in PCa diagnosis. This article aims to provide concise information on the current findings that impact prostate cancer research. Results of enzyme-linked immunosorbent assays (ELISA) for single biomarkers, quantitative polymerase chain reaction (PCR)-based assays for DNA/RNA markers will be reviewed in addition to high-throughput proteomic profiling of PCa specimens. The advantages/disadvantages of tissue, blood, urine or seminal plasma as sources for potential biomarkers are discussed emphasizing the consequences for PCa diagnosis. In summary, the majority of promising marker candidates available today needs further validation. Some of the identified markers have the potential to yield novel prognostic tools for PCa, provide novel insights into its pathophysiology, and contribute to the establishment of novel treatment strategies.
目前正在评估用于前列腺癌（PCa）诊断的新型生物标志物的效用。本文旨在提供有关影响前列腺癌研究的当前发现的简要信息。除了对PCa标本进行高通量蛋白质组分析外，还将综述针对单一生物标志物的酶联免疫吸附测定（ELISA）结果、基于定量聚合酶链反应（PCR）的DNA/RNA标志物测定结果。讨论了组织、血液、尿液或精浆作为潜在生物标志物来源的优缺点，强调了其对PCa诊断的影响。总之，当今大多数有前景的候选标志物都需要进一步验证。一些已鉴定的标志物有可能产生用于PCa的新型预后工具，为其病理生理学提供新的见解，并有助于建立新的治疗策略。
